News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
8,459 Results
Type
Article (745)
Company Profile (1)
Press Release (7713)
Multimedia
Podcasts (6)
Webinars (1)
Section
Business (3077)
Career Advice (16)
Deals (381)
Drug Delivery (7)
Drug Development (1285)
Employer Resources (3)
FDA (257)
Job Trends (159)
News (4619)
Policy (356)
Tag
Academia (31)
Accelerated approval (4)
ADA (3)
Alliances (959)
ALS (1)
Alzheimer's disease (17)
Antibody-drug conjugate (ADC) (9)
Approvals (265)
Artificial intelligence (14)
ASCO (3)
Autoimmune disease (5)
Automation (2)
Bankruptcy (10)
Best Places to Work (94)
BIOSECURE Act (1)
Biosimilars (20)
BioSpace Insights (1)
Biotechnology (1)
Bladder cancer (1)
Breast cancer (9)
Cancer (92)
Cardiovascular disease (7)
Career advice (15)
Cell therapy (7)
Clinical research (1105)
Collaboration (73)
Compensation (5)
COVID-19 (14)
C-suite (31)
Cystic fibrosis (6)
Data (78)
Depression (1)
Diabetes (8)
Diagnostics (46)
Digital health (5)
Drug discovery (3)
Drug pricing (22)
Earnings (803)
Editorial (1)
Employer branding (1)
Employer resources (2)
Events (846)
Executive appointments (24)
FDA (294)
Funding (33)
Generative AI (2)
Gene therapy (8)
GLP-1 (71)
Government (60)
Guidances (6)
Healthcare (141)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (1)
Immunology and inflammation (10)
Immuno-oncology (1)
Indications (3)
Infectious disease (18)
Inflammatory bowel disease (5)
Inflation Reduction Act (1)
Influenza (2)
Intellectual property (2)
Interviews (4)
IPO (179)
IRA (10)
Job creations (69)
Job search strategy (15)
Labor market (2)
Layoffs (13)
Legal (83)
Lung cancer (40)
Machine learning (2)
Management (1)
Manufacturing (15)
MASH (16)
Medical device (75)
Medtech (77)
Mergers & acquisitions (197)
Metabolic disorders (57)
mRNA (5)
NASH (6)
Neurodegenerative disease (11)
Neuropsychiatric disorders (4)
Neuroscience (40)
NextGen: Class of 2026 (70)
Non-profit (36)
Now hiring (1)
Obesity (38)
Opinion (7)
Ovarian cancer (1)
Pain (1)
Parkinson's disease (3)
Patents (4)
People (984)
Pharmacy benefit managers (3)
Phase 1 (261)
Phase 2 (452)
Phase 3 (416)
Pipeline (141)
Policy (17)
Postmarket research (115)
Preclinical (87)
Rare diseases (15)
Real estate (73)
Recruiting (1)
Regulatory (281)
Reports (1)
Research institute (29)
Resumes & cover letters (1)
RNA editing (1)
Schizophrenia (10)
Series A (10)
Series B (6)
Special edition (1)
Startups (62)
Supply chain (2)
The Weekly (6)
Vaccines (11)
Venture capital (5)
Weight loss (31)
Date
Today (5)
Last 7 days (13)
Last 30 days (28)
Last 365 days (333)
2026 (221)
2025 (318)
2024 (413)
2023 (371)
2022 (665)
2021 (669)
2020 (584)
2019 (520)
2018 (377)
2017 (536)
2016 (489)
2015 (451)
2014 (374)
2013 (333)
2012 (325)
2011 (309)
2010 (336)
Location
Africa (19)
Alabama (1)
Arizona (4)
Asia (269)
Australia (66)
California (275)
Canada (9)
China (9)
Colorado (2)
Connecticut (29)
Europe (2299)
Florida (2)
Georgia (9)
Illinois (10)
India (2)
Indiana (10)
Japan (8)
Kansas (1)
Maryland (2)
Massachusetts (59)
Michigan (4)
Missouri (1)
Nevada (1)
New Hampshire (1)
New Jersey (12)
New York (15)
North Carolina (6)
Northern California (72)
Ohio (1)
Oklahoma (1)
Oregon (1)
Pennsylvania (8)
South America (21)
Southern California (149)
Tennessee (1)
Texas (6)
United States (464)
Utah (1)
Virginia (1)
Washington D.C. (2)
Washington State (17)
8,459 Results for "boehringer ingelheim fremont".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies
· New research team expands capabilities at Boehringer’s U.S. R&D site in Ridgefield, Connecticut.
July 9, 2026
·
1 min read
Press Releases
Boehringer Ingelheim Spotlights Next Generation of Veterinary Researchers
August 10, 2026
·
5 min read
Press Releases
Boehringer Ingelheim expands equine health pipeline with acquisition of Evax AG
August 11, 2026
·
3 min read
Policy
Germany rethinking drug price reforms after Lilly, Boehringer withdraw investments:
Reuters
Weeks after Boehringer Ingelheim and Eli Lilly retracted billions of dollar in German commitments, the nation’s government is reportedly changing a contentious element of its planned healthcare reforms.
June 15, 2026
·
2 min read
·
Nick Paul Taylor
Obesity
ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction
While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.
June 8, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Lilly and Boehringer roll back billions in German investments over health budget cuts
With Germany moving to curb healthcare spending, Eli Lilly and Boehringer Ingelheim have rethought plans to invest in facilities, including a manufacturing plant for GLP-1 drugs.
June 4, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
May 22, 2026
·
14 min read
Press Releases
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®
June 11, 2026
·
5 min read
Press Releases
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
July 16, 2026
·
6 min read
Press Releases
Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.
July 15, 2026
·
5 min read
1 of 846
Next
